SCHEMBL3283516

SCHEMBL3283516

COC(=O)c1cc2ccsc2n1Cc1cccc2ccc(F)cc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.70
LMNA P02545 3/20 0.70
MAPT P10636 7/20 0.69
TSHR P16473 7/20 0.49
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
TP53 P04637 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
RECQL P46063 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ESR1 P03372 1/20 0.46
USP2 O75604 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.44
F10 P00742 1/20 0.44
STAT3 P40763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277418 0.88 L3MBTL1 (0.74) L3MBTL1LMNAMAPTTSHRALDH1A1
SCHEMBL3277148 0.87 L3MBTL1 (0.52) L3MBTL1LMNAMAPTTSHRALDH1A1
SCHEMBL3276122 0.85 MAPT (0.68) L3MBTL1LMNAMAPTTSHRALDH1A1
SCHEMBL3276602 0.74 L3MBTL1 (0.54) L3MBTL1LMNAMAPTTSHRALDH1A1
SCHEMBL3276552 0.73 NOD2 (0.59) L3MBTL1MAPTTSHRALDH1A1SMN1; SMN2
SCHEMBL3276993 0.72 MAPT (0.68) L3MBTL1LMNAMAPTTSHRALDH1A1
SCHEMBL3280545 0.72 MAPT (0.51) LMNAMAPTTSHRALDH1A1HPGD
SCHEMBL2330694 0.71 L3MBTL1 (0.61) L3MBTL1LMNAMAPTTSHRALDH1A1
SCHEMBL3283484 0.71 NOD2 (0.53) L3MBTL1MAPTTSHRALDH1A1SMN1; SMN2
SCHEMBL3275247 0.70 KMT2A (0.46) L3MBTL1LMNAMAPTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
CN-101351446-B Novel fused pyrrole derivatives HOFFMANN LA ROCHE 2011-10-05 CN disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
CN-101351446-A Novel fused pyrrole derivatives HOFFMANN LA ROCHE (CH) 2009-01-21 CN disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 L3MBTL1 4757/4885LMNA 3734/4885MAPT 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.